Clinical Trials Logo

Filter by:
NCT ID: NCT04928586 Active, not recruiting - Clinical trials for Interstitial Lung Disease

Immunosuppressant Combined With Pirfenidone in CTD-ILD

Start date: August 16, 2019
Phase: Phase 4
Study type: Interventional

A prospective cohort study was used to observe the efficacy and safety of different immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong University for 36 months.The main research endpoints are lung function, patient dyspnea score, 6-minute walking distance, imaging indicators, primary disease activity, adverse reactions, etc.

NCT ID: NCT04928560 Active, not recruiting - ULTRASOUND Clinical Trials

Diagnosis of Superficial Lymphadenopathy

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to study the application of CEUS and SMI technology in superficial lymph node lesions (metastasis, lymphoma, inflammation, etc.), and to provide some diagnostic ideas for non-invasive diagnosis of lymph node lesions.

NCT ID: NCT04927104 Active, not recruiting - Clinical trials for Osteoarthritis of the Knee

Exploratory Study on Safety of PEEK Knee Prosthesis

Start date: June 25, 2021
Phase: N/A
Study type: Interventional

In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis and be followed up 3, 6, and 12 months after surgery. The safety of the knee prosthesis for total knee arthroplasty will be investigated based on X-ray, magnetic resonance imaging, thin-section CT, hematological indexes, knee function, complications and the occurrence of serious adverse events at the 12-month follow-up.

NCT ID: NCT04925206 Active, not recruiting - Clinical trials for Transfusion Dependent Beta-Thalassaemia

A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia

ET-01
Start date: August 17, 2021
Phase: Phase 1
Study type: Interventional

This is a single-arm, open label, multi-center, single-dose phase 1 study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using ET-01.

NCT ID: NCT04924959 Active, not recruiting - Clinical trials for Cancer Patients With PICC

Construction and Validation of Risk Prediction Model for PICC Catheter Displacement

Start date: June 27, 2019
Phase:
Study type: Observational

The occurrence of PICC catheter displacement is caused by many factors. In order to predict the risk of PICC and early warn high-risk patients, this study prospectively included patients with PICC catheter in a three Grade-A hospitals in June 2019, analyzed a variety of related factors, built a scientific and effective risk prediction model of PICC catheter displacement, and verified the goodness of fit and differential validity of the model.

NCT ID: NCT04924608 Active, not recruiting - Neurofibromatosis 1 Clinical Trials

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

KOMET
Start date: November 19, 2021
Phase: Phase 3
Study type: Interventional

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.

NCT ID: NCT04924179 Active, not recruiting - Clinical trials for Patients With Advanced Metastatic Colorectal Cancer

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer

NCT ID: NCT04924062 Active, not recruiting - Clinical trials for Biliary Tract Carcinoma

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Start date: July 10, 2020
Phase: Phase 3
Study type: Interventional

In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).

NCT ID: NCT04921774 Active, not recruiting - Clinical trials for Heart Transplant Rejection

Research on Patients With Heart Transplantation

Start date: January 1, 2020
Phase:
Study type: Observational

This trial was a single-center, prospective cohort study.The purpose of this clinical research is to evaluate the accuracy of combining multimodality MR Imaging with circulating exosomal miRNA expression to diagnose acute rejection in patients with heart transplantation,thus it may be helpful for timely intervention to improve the patient's prognosis.

NCT ID: NCT04918901 Active, not recruiting - Severe COVID-19 Clinical Trials

Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19

Start date: May 1, 2020
Phase:
Study type: Observational [Patient Registry]

Novel Coronavirus Pneumonia (COVID-19) is the pneumonia caused by the 2019 novel coronavirus infection. Critically ill patients with this disease develop dyspnea and hypoxemia, and even further aggravate acute respiratory distress syndrome, septic shock, coagulation dysfunction, and multiple organ failure. Since February 15, 2020, the 171-member medical team of the Second Affiliated Hospital of Zhejiang University School of Medicine has taken over the Intensive Care Unit of the Cancer Center of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and the Intensive Care Unit of the West Hospital of Union Hospital to carry out severe and critical care. Treatment of patients with new coronary pneumonia. In clinical practice, combined with the changes in chest CT imaging of severe COVID-19 patients, it has been found that some laboratory indicators of severe patients can effectively judge the clinical prognosis and outcome of patients, but there is no relevant retrospective study with large sample size so far.